Want to see SE:SOBI full AI Analyst Report?
Top Page
Swedish Orphan Biovitrum AB
(SOBI)
Select Model
Select Model
Rating:60Neutral
Price Target:
kr489.00
▲(6.91% Upside)
Action:Reiterated
Date:07/17/26
The score is primarily supported by strong cash generation and a generally sound balance sheet, but it is held back by materially weaker net profitability versus prior years and an extremely high P/E multiple. Technicals are moderately supportive (above key longer-term averages) but momentum readings are mixed, limiting the upside contribution.
Positive Factors
Free Cash Flow Strength
Sobi’s growing TTM free cash flow and strong operating cash generation provide durable financial flexibility to fund R&D, support launches, and pursue partnerships without relying solely on external financing. High FCF relative to net income also supports earnings quality and balance-sheet resilience over months.
Negative Factors
Compressed Net Profitability
Net income has fallen materially from prior peaks, creating a large gap between EBITDA and reported profit. Below-the-line or non-operating pressures have compressed net margins, increasing earnings volatility and reducing retained earnings available for reinvestment or to improve returns on equity over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Free Cash Flow Strength
Sobi’s growing TTM free cash flow and strong operating cash generation provide durable financial flexibility to fund R&D, support launches, and pursue partnerships without relying solely on external financing. High FCF relative to net income also supports earnings quality and balance-sheet resilience over months.
Read all positive factors
Swedish Orphan Biovitrum AB (SOBI) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr151.88B
Dividend YieldN/A
Average Volume (3M)396.16K
Price to Earnings (P/E)110.9
Beta (1Y)0.99
Revenue Growth13.54%
EPS Growth-68.79%
CountrySE
Employees2,119
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)3.97
Shares Outstanding357,412,840
10 Day Avg. Volume356,894
30 Day Avg. Volume396,160
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)3.04
Price to Sales (P/S)4.06
P/FCF Ratio13.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr545.00Price Target Upside19.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)18.91
Revenue Forecast (FY)kr32.95B
Swedish Orphan Biovitrum AB Business Overview & Revenue Model
Company Description
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Ha...
How the Company Makes Money
Sobi makes money primarily by selling prescription medicines (its rare-disease therapies) to healthcare systems, hospitals, and pharmacies in the markets where it commercializes products directly. Revenue is generated from net product sales, typic...
Swedish Orphan Biovitrum AB Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
66
Positive
Cash Flow
73
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.62B | 28.24B | 26.03B | 22.12B | 18.79B | 15.53B |
| Gross Profit | 14.05B | 12.32B | 20.24B | 9.95B | 13.98B | 12.04B |
| EBITDA | 13.23B | 10.96B | 9.30B | 7.23B | 6.05B | 5.71B |
| Net Income | 1.38B | 478.00M | 3.88B | 2.41B | 2.64B | 2.68B |
Balance Sheet | ||||||
| Total Assets | 82.89B | 67.43B | 75.44B | 74.03B | 52.50B | 48.66B |
| Cash, Cash Equivalents and Short-Term Investments | 1.08B | 1.04B | 1.14B | 904.00M | 1.36B | 1.04B |
| Total Debt | 17.59B | 11.49B | 16.73B | 20.48B | 9.10B | 10.91B |
| Total Liabilities | 40.62B | 29.71B | 35.15B | 40.16B | 25.97B | 25.46B |
| Stockholders Equity | 42.26B | 37.72B | 40.29B | 33.87B | 26.52B | 23.20B |
Cash Flow | ||||||
| Free Cash Flow | 7.25B | 8.52B | 4.38B | -473.00M | 3.10B | 5.10B |
| Operating Cash Flow | 7.86B | 8.56B | 7.39B | 4.47B | 4.58B | 5.47B |
| Investing Cash Flow | -12.90B | -4.29B | -3.09B | -21.90B | -1.48B | -367.00M |
| Financing Cash Flow | 5.04B | -4.32B | -4.00B | 17.01B | -2.90B | -4.47B |
Swedish Orphan Biovitrum AB Technical Analysis
Negative
457.40
Price Trends
456.58
Negative
437.38
Positive
395.07
Positive
Market Momentum
-4.50
Positive
41.35
Neutral
33.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SOBI, the sentiment is Negative. The current price of 457.4 is above the 20-day moving average (MA) of 454.59, above the 50-day MA of 456.58, and above the 200-day MA of 395.07, indicating a neutral trend. The MACD of -4.50 indicates Positive momentum. The RSI at 41.35 is Neutral, neither overbought nor oversold. The STOCH value of 33.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SOBI.
Swedish Orphan Biovitrum AB Peers Comparison
UnderperformOutperform
Sector (55)
SE:SOBI
Swedish Orphan Biovitrum AB
440.40
159.40
56.73%
SE:HNSA
Hansa Biopharma AB
39.16
9.38
31.50%
SE:MVIR
Medivir AB
1.66
-0.31
-15.56%
SE:ORX
Orexo AB
15.20
-5.25
-25.67%
SE:NEWBRY
Newbury Pharmaceuticals AB
2.72
0.13
5.02%
SE:DICOT
Dicot Pharma AB
0.21
-0.44
-68.10%
Swedish Orphan Biovitrum AB Corporate Events
Sobi lifts 2026 outlook as Q2 revenue surges and gout pipeline advances
Jul 16, 2026
Sobi reported strong second-quarter 2026 results, with total revenue rising 29% at constant exchange rates to SEK 7.8 billion and adjusted EBITA up 31%, driven by robust growth in both haematology and immunology franchises. Strategic portfolio sal...
Sobi Moves to Repurchase Class C Shares to Support Employee Incentive Programme
Jul 15, 2026
Sobi’s board has decided to repurchase all issued class C shares to secure the company’s commitments under its long-term All Employee incentive programme for permanent staff. The repurchase, conditional on subscription and payment by S...
Sobi hit with FDA manufacturing setback on NASP gout therapy, but efficacy concerns ruled out
Jun 26, 2026
Sobi has received a complete response letter from the U.S. Food and Drug Administration for its biologics license application for NASP, an investigational therapy for adult patients with uncontrolled gout. The agency requested additional chemistry...
Sobi’s Tryngolza cuts pancreatitis risk 85% in severe hypertriglyceridemia trial analysis
May 26, 2026
Sobi reported new pooled Phase 3 data showing that its RNA-targeted therapy Tryngolza (olezarsen) cut the relative risk of acute pancreatitis by 85% and reduced triglyceride levels by up to 66% in patients with severe hypertriglyceridemia after si...
Sobi Posts Positive Phase 3 Data for Gout Drug Pozdeutinurad
May 22, 2026
Sobi reported positive topline results from its pivotal Phase 3 REDUCE 2 trial of pozdeutinurad, a once-daily oral URAT1 inhibitor for adults with gout, including those inadequately controlled by existing therapies. Both 50 mg and 75 mg doses met ...
Sobi AGM Backs Board, Incentive Plans and New Share Issue Mandate
May 6, 2026
Shareholders in Swedish Orphan Biovitrum approved all board proposals at the company’s annual general meeting, including the adoption of the 2025 accounts and the decision to carry forward retained earnings, while granting discharge of liabi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.